{
  "id": 15505054,
  "title": "Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.",
  "url": "https://urgent.news/2026/10/18/viking-therapeutics-just-raised-575-million-heres-what-it-means-for",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-18T22:30:00.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/10/18/viking-therapeutics-just-raised-575-million-heres/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Viking Therapeutics (VKTX) has successfully raised $575 million following a promising maintenance trial, which bolsters the investment appeal of the stock. The company secured $316 million from a stock offering priced at $35 per share, and an additional $258.75 million through convertible senior notes, resulting in a total gross of $575 million.\n\nViking Therapeutics is currently conducting extensive phase 3 trials for its GLP-1 and GIP agonist, VK2735. These trials include 78-week phases for subcutaneous (injectable) treatments in obesity (Vanquish-1) and type 2 diabetes and obesity (Vanquish-2). Moreover, the initiation of 68-week phase 3 trials for oral VK2735 in obesity (Sunrise-1) and type 2 diabetes with obesity (Sunrise-2) has been announced as well.\n\nFurthermore, Viking is in the second phase of its maintenance trial, in which the final 12 weeks of oral VK2735 maintenance doses will follow a 21-week subcutaneous dose. This trial's length and scale, combined with Viking's financial constraints, suggest that the company may need to manage cash reserves until at least 2030, according to Wall Street consensus.\n\nThe $575 million cash infusion will not only fund VK2735 trials but also support the development of Viking's pipeline, including an amylin agonist, VK3019, for patients who cannot tolerate GLP-1 agonists or in combination with them. Other pharmaceutical giants, Eli Lilly and Novo Nordisk, are also exploring amylin agonists.\n\nWhile investors eagerly await the outcome of the maintenance trial in 2027, Vanquish-1 and Vanquish-2 trials later in 2028, and Sunrise-1 and Sunrise-2 likely in 2028, Viking's future hinges on the success of VK2735. Despite this, the recent cash raise reduces potential risk, enabling the company to pursue value generation for investors.",
  "summary": "Viking Therapeutics raised $575 million to fund major obesity drug trials, develop its pipeline, and support commercial development of any approvals for VK2735.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.",
        "url": "https://urgent.news/2026/10/18/viking-therapeutics-just-raised-575-million-heres-what-it-means-for-15512662",
        "published": "2026-10-18T22:50:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}